Richard Stebbings

Summary

Affiliation: National Institute for Biological Standards and Control
Country: UK

Publications

  1. pmc Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine
    Richard Stebbings
    Division of Biotherapeutics, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom
    PLoS ONE 7:e50397. 2012
  2. ncbi request reprint Mechanisms of protection induced by attenuated simian immunodeficiency virus
    Richard J Stebbings
    Division of Immunobiology, Division of Retrovirology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, United Kingdom
    Virology 296:338-53. 2002
  3. ncbi request reprint Vaccination with live attenuated simian immunodeficiency virus for 21 days protects against superinfection
    Richard Stebbings
    Division of Immunology, NIBSC, Hertfordshire EN6 3QG, United Kingdom
    Virology 330:249-60. 2004
  4. pmc CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus
    Richard Stebbings
    Division of Immunology, NIBSC, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
    J Virol 79:12264-72. 2005
  5. pmc Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model
    Mark Page
    Division of Retrovirology, HPA NIBSC, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK
    Retrovirology 9:56. 2012
  6. ncbi request reprint Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy
    Lucy Findlay
    Biotherapeutics Group, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire EN6 3QG, UK
    J Immunol Methods 371:134-42. 2011
  7. doi request reprint Antibody C region influences TGN1412-like functional activity in vitro
    Christina Ball
    National Institute for Biological Standards and Control, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
    J Immunol 189:5831-40. 2012
  8. pmc Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques
    Neil Berry
    Division of Retrovirology, National Institute for Biological Standards and Control, Health Protection Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom
    PLoS ONE 6:e23092. 2011
  9. pmc Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release
    David Eastwood
    Biotherapeutics Group, NIBSC, Potters Bar, Hertfordshire, UK
    Br J Clin Pharmacol 76:299-315. 2013
  10. doi request reprint Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8)
    Neil Berry
    Division of Retrovirology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK
    J Gen Virol 89:2240-51. 2008

Detail Information

Publications18

  1. pmc Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine
    Richard Stebbings
    Division of Biotherapeutics, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom
    PLoS ONE 7:e50397. 2012
    ..MV1-F4 carrying HIV-1 Clade B inserts induces robust boostable immunity in non-human primates. These results support further exploration of the MV1-F4 vector modality in vaccination strategies that may limit HIV-1 infectivity...
  2. ncbi request reprint Mechanisms of protection induced by attenuated simian immunodeficiency virus
    Richard J Stebbings
    Division of Immunobiology, Division of Retrovirology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, United Kingdom
    Virology 296:338-53. 2002
    ..These data do not support the hypothesis that protection conferred by live attenuated SIV is mediated by the induction of vigorous T-cell responses upon rechallenge...
  3. ncbi request reprint Vaccination with live attenuated simian immunodeficiency virus for 21 days protects against superinfection
    Richard Stebbings
    Division of Immunology, NIBSC, Hertfordshire EN6 3QG, United Kingdom
    Virology 330:249-60. 2004
    ..These findings imply that innate immunity or non-immune mechanisms are a significant component of early protection against superinfection conferred by inoculation with live attenuated SIV...
  4. pmc CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus
    Richard Stebbings
    Division of Immunology, NIBSC, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
    J Virol 79:12264-72. 2005
    ....
  5. pmc Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model
    Mark Page
    Division of Retrovirology, HPA NIBSC, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK
    Retrovirology 9:56. 2012
    ....
  6. ncbi request reprint Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy
    Lucy Findlay
    Biotherapeutics Group, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire EN6 3QG, UK
    J Immunol Methods 371:134-42. 2011
    ..Overall, the antibodies tested could be ranked as follows: Tysabri<Avastin<Herceptin<Campath-1H<TGN1412, with only the "superagonistic" CD28 monoclonal antibody (TGN1412) stimulating IL-2 release and cell proliferation...
  7. doi request reprint Antibody C region influences TGN1412-like functional activity in vitro
    Christina Ball
    National Institute for Biological Standards and Control, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
    J Immunol 189:5831-40. 2012
    ..We propose that the Fc, potentially through restricting flexibility, maintains a favorable V region conformation to allow superagonistic activity. These findings have important implications for Ab design strategies...
  8. pmc Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques
    Neil Berry
    Division of Retrovirology, National Institute for Biological Standards and Control, Health Protection Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom
    PLoS ONE 6:e23092. 2011
    ..Immune correlates of vaccine-induced protection have also been difficult to identify, particularly those measurable in the peripheral circulation...
  9. pmc Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release
    David Eastwood
    Biotherapeutics Group, NIBSC, Potters Bar, Hertfordshire, UK
    Br J Clin Pharmacol 76:299-315. 2013
    ..To determine if cytokine release with a solid phase assay is predictive of adverse responses for a range of therapeutic mAbs...
  10. doi request reprint Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8)
    Neil Berry
    Division of Retrovirology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK
    J Gen Virol 89:2240-51. 2008
    ..The role of innate and intrinsic anti-retroviral immunity in the protection conferred by live attenuated SIV vaccines warrants careful study...
  11. doi request reprint Immunogenicity of a recombinant measles HIV-1 subtype C vaccine
    Richard Stebbings
    Division of Biotherapeutics, NIBSC, Potters Bar, Hertfordshire EN6 3QG, United Kingdom Electronic address
    Vaccine 31:6079-86. 2013
    ..These findings support further exploration of the MV1-F4 vector as a candidate HIV-1 subtype C vaccine or as part of a wider vaccine strategy. ..
  12. doi request reprint Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture
    Lucy Findlay
    Biotherapeutics Group, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK
    Cytokine 55:141-51. 2011
    ....
  13. doi request reprint Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412
    Lucy Findlay
    Biotherapeutics Group, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire EN6 3QG, UK
    J Immunol Methods 352:1-12. 2010
    ..It was concluded that immobilising mAbs by air-drying offers a useful in vitro method for detecting and quantifying pro-inflammatory activities of therapeutic mAbs...
  14. doi request reprint Safety of biologics, lessons learnt from TGN1412
    Richard Stebbings
    Biotherapeutics Group, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire EN6 3QG, UK
    Curr Opin Biotechnol 20:673-7. 2009
    ..Perhaps the most important lesson is that greater caution needs to be exercised when evaluating new biologics...
  15. pmc Vaccination with live attenuated simian immunodeficiency virus causes dynamic changes in intestinal CD4+CCR5+ T cells
    Bo Li
    Biotherapeutics Group, National Institute of Biological Standards and Control Health Protection Agency, Potters Bar, Hertfordshire, UK
    Retrovirology 8:8. 2011
    ..abstract:..
  16. pmc Allogeneic lymphocyte transfer in MHC-identical siblings and MHC-identical unrelated Mauritian cynomolgus macaques
    Edward T Mee
    Division of Virology, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, South Mimms, Hertfordshire, United Kingdom
    PLoS ONE 9:e88670. 2014
    ....
  17. ncbi request reprint "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics
    Richard Stebbings
    Biotherapeutics Group, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom
    J Immunol 179:3325-31. 2007
    ....
  18. doi request reprint How do we assure the quality of biological medicines?
    Colin Longstaff
    Division of Biotherapeutics Section, National Institute for Biological Standards and Control, Blanche Lane, S Mimms, Herts EN6 3QG, UK
    Drug Discov Today 14:50-5. 2009
    ..This review includes historical and regulatory background and three examples of problems seen with biotherapeutics: streptokinase, heparin and TGN1412...